Form 4 for NMRA Neumora Therapeutics, Inc.
Accepted 2023-09-21 00:00:00 ET · period of report 2023-09-19 · accession 0001209191-23-050240 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2023-09-21 | 2023-09-19 | NMRA | FMR LLC | See Remark 1 | C - Cnv Deriv | — | +3.71M | 88.3K | New | — |
| DMI | 2023-09-21 | 2023-09-19 | NMRA | FMR LLC | See Remark 1 | C - Cnv Deriv | — | -3.71M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-19 | C | A | 3,475,646 | — | 5,387,375 | I F-Prime Capital Partners Life Sciences Fund VII LP | — | — | (F1) On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| 2 | Common | Common Stock | 2023-09-19 | C | A | 84,965 | — | 5,472,340 | I F-Prime Capital Partners Life Sciences Fund VII LP | — | — | (F1) On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| 3 | Common | Common Stock | 2023-09-19 | C | A | 63,724 | — | 63,724 | I F-Prime Inc. | — | — | (F1) On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| 4 | Common | Common Stock | 2023-09-19 | C | A | 88,289 | — | 88,289 | I FBRI LLC | — | — | (F1) On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| 5 | Derivative | Series A-2 Preferred Stock | 2023-09-19 | C | D | 88,289 | — | 0 | I FBRI LLC | — · — to — | 88,289 Common Stock | (F1) On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| 6 | Derivative | Series A-2 Preferred Stock | 2023-09-19 | C | D | 63,724 | — | 0 | I F-Prime Inc. | — · — to — | 63,724 Common Stock | (F1) On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| 7 | Derivative | Series A-2 Preferred Stock | 2023-09-19 | C | D | 3,475,646 | — | 0 | I F-Prime Capital Partners Life Sciences Fund VII LP | — · — to — | 3,475,646 Common Stock | (F1) On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| 8 | Derivative | Series B Preferred Stock | 2023-09-19 | C | D | 84,965 | — | 0 | I F-Prime Capital Partners Life Sciences Fund VII LP | — · — to — | 84,965 Common Stock | (F1) On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |